Liposomes in tumor treatment: a double-edged sword

Area of Science:

• Nanomedicine
• Immunology
• Pharmacology

Background:

• FDA-approved liposomal drugs offer improved toxicity and delivery.
• Emerging evidence shows liposomes can have pro-angiogenic and immunosuppressive effects.
• Complement system activation is implicated in these adverse liposomal effects.

Purpose of the Study:

• To review the role of complement system activation in liposomal drug adverse effects.
• To analyze interactions between liposomes, complement proteins, and the tumor microenvironment.
• To identify strategies for optimizing nanocarrier design for improved cancer nanomedicine.

Main Methods:

• Literature review and synthesis of existing evidence.
• Analysis of dynamic interactions between liposomal formulations, complement proteins, and the tumor microenvironment.
• Elucidation of mechanisms underlying liposome-complement interactions.

Main Results:

• Complement activation by liposomes contributes to pro-angiogenic and immunosuppressive effects.
• These effects can compromise the therapeutic efficacy of liposomal drugs.
• Understanding these interactions is crucial for optimizing liposomal drug design.

Conclusions:

• Next-generation liposomal therapeutics require designs that minimize immunogenic potential.
• Optimizing nanocarrier design can enhance efficacy and reduce adverse effects.
• This framework provides insights for translational cancer nanomedicine development.